Regulatory Actions Impacting Biologics
· siegfried schmitt
Source Summary
Three regulatory actions are coming together in an effort to move biologics, the gene therapy, and the ATMP platform forward quickly, say Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, Parexel.
Advertisement